Bristol-Myers to revise non-GAAP reporting; Q1 2022 impact of -$0.10/share from Acquired IPRD

BRISTOL MYERS SQUIBB CO

Starting Q1 2022, non-GAAP results will include significant R&D charges from asset acquisitions and licensing, previously excluded.
2021 non-GAAP diluted EPS revised down to $7.16 from $7.51; 2020 GAAP shows new $12.5B Acquired IPRD line.
Preliminary Q1 2022 estimate: net negative impact of approx. $0.10/share from Acquired IPRD charges and licensing income.
Change follows SEC discussions; historical financials for 2020-2021 restated for comparability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.